Remune

also known as HIV-1 Immunogen

Developed for: HIV infectious disease · AIDS · hypoproteinemia, hypercatabolic
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Agouron Pharmaceuticals · The Immune Response Corporation · CIHR Canadian HIV Trials Network · Canadian Institutes of Health Research (CIHR) · Immune Response BioPharma, Inc.
+4 more
· Ontario HIV Treatment Network · Ottawa Hospital Research Institute · Smartfish AS · University of Rochester

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT04131426	Apr 2020 → Jan 2021	digestive system cancer, hypoproteinemia, hypercatabolic, lung cancer	University of Rochester	Completed	No outcome recorded
Phase 1	NCT00006495	? → Sep 2004	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT00212888	Apr 2004 → Jul 2010	HIV infectious disease	Ottawa Hospital Research Institute	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT02291809	Nov 2017 → Nov 2019	AIDS	Immune Response BioPharma, Inc.	Unknown	No outcome recorded
Phase 2	NCT00005001	—	HIV infectious disease	Agouron Pharmaceuticals	Completed	No outcome recorded
Phase 33 trials
Phase 3	NCT00005758	? → Sep 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 3	NCT00005002	—	HIV infectious disease	Agouron Pharmaceuticals	Unknown	No outcome recorded
Phase 3	NCT00002359	—	HIV infectious disease	The Immune Response Corporation	Completed	No outcome recorded
Phase not applicable2 trials
—	NCT00002172	—	HIV infectious disease	The Immune Response Corporation	Completed	No outcome recorded
—	NCT00000943	? → Nov 2005	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	Remune	“The purpose of this study is to see if it is effective to add an HIV vaccine (Remune) to the anti-HIV drug combination of Combivir (zidovudine plus lamivudine) and nelfinavir.” NCT00005002 ↗ 10 “The purpose of this study is to see how the vaccines Remune (HIV-1 immunogen) and vCP1452 affect immune responses in patients who also are taking anti-HIV medications.” NCT00006495 ↗ “An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml” NCT00002172 ↗ “This study originally added an HIV vaccine called Remune to treat patients.” NCT00005758 ↗ “Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC” NCT00212888 ↗ “Remune is an experimental HIV vaccine.” NCT00000943 ↗ “HIV-1 immunogen (Remune)” NCT00002359 ↗ “HIV vaccine (Remune)” NCT00005001 ↗ NCT00212888 ↗ NCT02291809 ↗ NCT04131426 ↗
Known as	HIV-1 Immunogen	“10 Units of HIV-1 Immunogen (Remune)” NCT00002359 ↗
Modality	Vaccine	“an HIV vaccine (Remune)” NCT00000943 ↗
Route	Intramuscular	“Remune(TM) 1 ml i.m.” NCT00212888 ↗